Technology

Syra Health Announces Closing of $2.1 Million Public Offering

Published

1 week ago

September 13, 2024

CARMEL, Ind., Sept. 13, 2024 /PRNewswire/ — Syra Health Corp. (NASDAQ: SYRA), (“Syra Health” or the “Company”), a healthcare technology company powering better health by providing meaningful solutions, today announced the closing of its previously announced public offering of an aggregate of 3,203,125 shares of its Class A common stock, Series A warrants to purchase up to 3,203,125 shares of Class A common stock and Series B warrants to purchase up to 3,203,125 shares of Class A common stock (all the warrants, collectively, the “Series Warrants”), at a combined public offering price of $0.64 per share and accompanying Series Warrants. The Series Warrants have an exercise price of $0.64 per share and are exercisable immediately upon issuance. The Series A warrants expire on the eighteen-month anniversary of the initial issuance date and the Series B warrants expire on the five-year anniversary of the initial issuance date.

Rodman & Renshaw LLC acted as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering were approximately $2.1 million before deducting the placement agent’s fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Series Warrants, if fully exercised on a cash basis, will be approximately $4.1 million. No assurance can be given that any of the Series Warrants will be exercised. The Company intends to use the net proceeds from this offering for application development, sales and marketing, research and development and for general corporate purposes, including working capital, operating expenses, and capital expenditures.

The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-281583), which was declared effective by the Securities and Exchange Commission (the “SEC”) on September 11, 2024. The offering was made only by means of a prospectus forming part of the effective registration statement relating to the offering. A final prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus may be obtained on the SEC’s website at http://www.sec.gov and may also be obtained by contacting Rodman & Renshaw LLC at 600 Lexington Avenue, 32nd Floor, New York, NY 10022, by telephone at (212) 540-4414, or by email at info@rodm.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

ABOUT SYRA HEALTH

Syra Health is a healthcare technology company powering better health in challenging areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology products. Syra Health’s offerings are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government. For more information, please visit www.syrahealth.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements regarding the anticipated use of proceeds from the offering, the exercise of the Series Warrants prior to their expiration, the Company’s operations and business strategy, and the Company’s expected financial results. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty, changes in circumstances and market and other conditions. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

For Investor or Media Inquiries:
Syra Health
IR/PR and Marketing Director
Christine Drury
317-385-9227
christined@syrahealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/syra-health-announces-closing-of-2-1-million-public-offering-302248040.html

SOURCE Syra Health

Technology

Summit of Whose Future? Girls Have the Answers: Leaders Must Listen

Published

1 hour ago

September 21, 2024

Young Women Activists Launch “What Girls Want,” Demand World Leaders Put Girls at the Center of Summit of the Future

NEW YORK, Sept. 21, 2024 /PRNewswire/ — Today in New York, more than 50 young women from around the world – including Nobel Prize Laureate Malala Yousafzai – gathered to take government to task for failing to prioritize girls and young women in the upcoming Summit of the Future. The group is backed by acoalition of girl-centered non-profit organizations, institutions, and funds who synthesized the demands of girls at www.whatgirlswant.com.

At a demonstration near the UN, alongside life-size cutouts of world leaders dressed ironically as “girl experts”, the activists delivered a strong message: world leaders aren’t the experts on what girls want for their futures – girls are.

Eylül Erçin, 19, from Türkiye, shared: “The time has passed for girls and young women to be treated as mere afterthoughts. Leaders must include us in the foundational design of these processes, ensuring that our priorities are integrated into shaping the future we will inherit. Anything less is unacceptable.”

Today’s event is about more than calling out a process failure. Girls i from around the world delivered a forward-looking call to action this week. They expect governments, institutions, and community leaders to step up and help shape a more equitable future.

Alongside fellow activists, Malala said: “Even at 27, I know better than to assume I understand best what girls want. Everywhere I go, girls are eager to share their vision for their futures. As adults, it is our job to listen, fund their work and follow their lead. It is not too late for world leaders to do right by girls. They can start by prioritizing their demands in tomorrow’s final Summit deliberations and by investing resources to match their words.”

The evidence is clear: investing in girls and delivering on their rights transforms economies, societies, and the environment, advancing the SDGs and building a future that girls deserve.

About What Girls Want

This effort was produced by a collaboration of girl-centered organizations, institutions, funders, and allies. The campaign is anchored around work to collate insights, data, and stories from 20+ public consultations with girls and young women over the past decade, driven by a shared desire to center girls’ demands in spaces where they are being ignored.

Contact:

whatgirlswantpress@gmail.com

nate.powers@edelman.com

Logo – https://mma.prnewswire.com/media/2384993/Women_Deliver_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/summit-of-whose-future-girls-have-the-answers-leaders-must-listen-302254570.html

Technology

48-Hour Saudi Visa Processing, Major Discounts and Unmissable Giveaways – Only at ‘Spectacular Saudi’ in Mumbai

Published

3 hours ago

September 21, 2024

NEW DELHI, Sept. 21, 2024 /PRNewswire/ — Saudi’s national tourism brand, ‘Saudi Welcome to Arabia’ is hosting its first-ever immersive consumer event ‘Spectacular Saudi’, from September 25 to October 2, from 2:00 p.m. – 10:30 p.m. at R2 Ground in BKC, Mumbai.

Slated to transport visitors straight to the Heart of Arabia; the 8-day immersive experience will give visitors a glimpse into Saudi’s many wonders and iconic experiences – all while extending the warm Saudi welcome. To give consumers a truly memorable experience Saudi is offering exclusive giveaways and discounts specially curated for Indian travellers.

What’s more, Indian travellers can fast-track their Saudi visas exclusively at the event. All you need is a valid Visa or Mastercard credit card! Head on over to one of eight dedicated Tasheer kiosks, ensure the name on the credit card matches the passport, and have sufficient funds available on the card. After that, sit back and relax as your visa will be in hand within 48 hours!

It has never been easier to visit Saudi. With the most seamless visa process offered to date, the excitement doesn’t end there. On the travel front, SAUDIA Airlines is offering special deals, including a buy one get 50% off on the second ticket if travelling business class. Additionally, all economy class tickets will be 15% off. Attendees will also have the chance to participate in daily giveaways for free flight tickets for two to Saudi. With over 50+ travel trade offers, visitors can access incredible cashback and discounts on Saudi travel packages. Additionally, those booking Saudi packages will enjoy complimentary cultural city tours. Group tour packages to Riyadh, Jeddah, and Dammam will be available exclusively at the event, starting at INR 99,999 for 5 nights.

Visitors can expect unique immersive experiences–including exhibits, culinary delights, Ardah dancers, Saudi coffee, traditional scents, and fashion–all under one roof. So don’t miss out and register here to experience a piece of Saudi, right in the heart of Mumbai.

Photo – https://mma.prnewswire.com/media/2511104/Spectacular_Saudi.jpg

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/48-hour-saudi-visa-processing-major-discounts-and-unmissable-giveaways–only-at-spectacular-saudi-in-mumbai-302254776.html

Technology

Indian Cancer Genome Atlas Launches the Country’s First Comprehensive Cancer Multi-Omics Data Portal

Published

3 hours ago

September 21, 2024

Offers open access to cancer data for research

NEW DELHI, Sept. 21, 2024 /PRNewswire/ — The Indian Cancer Genome Atlas (ICGA) has launched India’s first comprehensive cancer multi-omics data portal. This pioneering platform provides open access to clinically correlated data from Indian cancer patients, aimed at transforming cancer research and treatment for Indian populations.

Historically, cancer treatments in India have been based on Western data sets. However, cancers in Indian patients can differ significantly at the molecular level. ICGA’s mission is to create Indian-specific datasets to help researchers and clinicians develop personalized treatment protocols. This new open-access portal represents a monumental step in revolutionizing cancer research, specifically for Indian patients.

The ICGA cancer multi-omics portal is the first in India to offer data that includes DNA, RNA, and protein profiles of breast cancer patients, integrated with clinical outcomes. Currently, the platform consists of data from 50 breast cancer patients, with plans to expand to over 500 patients in the coming year. This data is freely accessible to the global research community under India’s PRIDE guidelines, which promote ethical sharing and collaboration in cancer research.

Key Highlights of this portal include:

India’s First Cancer Multi-Omics Data Portal: A comprehensive resource that offers detailed multi-omics data for breast cancer patients, including genomic and proteomic information.Based on cBioPortal Platform: Derived from the internationally recognized cBioPortal, this platform ensures seamless integration with global cancer research efforts.Initial Dataset from 50 Indian Patients: Provides clinically annotated DNA, RNA, and protein profiles, along with treatment histories and patient outcomes, with an aim to scale up to 500 in a year.Free Access Under PRIDE Guidelines: Adhering to responsible and ethical data-sharing practices, the portal is freely accessible to the scientific community.A Step Toward Precision Oncology for Indian Patients: This initiative is designed to enable the development of personalized cancer treatments tailored to Indian patients.Call for Collaboration: ICGA invites researchers worldwide to contribute and expand the platform, fostering global collaboration in cancer research.

Professor Shekhar C. Mande, Former DG-CSIR, Currently Senior Professor at Savitribai Phule Pune University
“Making this invaluable cancer data publicly accessible marks a pivotal step in accelerating scientific discoveries and enhancing patient outcomes. By openly sharing this data, we are empowering researchers, clinicians, and innovators to collaborate, explore new frontiers, and drive transformative breakthroughs in cancer treatment.”

Joint Statement from Dr JC Zenklusen – Director of The Cancer Genome Atlas (TCGA) at the NCI, NIH, USA, and Prof Sunil Badve – Vice Chair, Pathology Cancer Programs, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
“Fifteen years ago, when we launched TCGA, we could not have foreseen the remarkable progress cancer research would make. It is incredibly exciting to see ICGA advancing so rapidly and taking bold steps in revolutionizing cancer research. Understanding the genome of cancer patients will improve the treatment of Indians not only in India but also worldwide. We, both, encourage others with similar data to actively contribute to ICGA, so this initiative can grow even faster and drive greater breakthroughs.”

Dr. Anand Deshpande, Chairman and Managing Director at Persistent, and Non-Executive Director at ICGA
“We have made an excellent start with this groundbreaking multi-omics cancer portal. Cancer touches all of us, and the need for more effective, personalized treatments—especially tailored to the unique genetic and environmental factors in India—is urgent. This portal will empower researchers with crucial data to advance customized cancer research for better treatment outcomes. I encourage everyone to contribute and support this vital cause, helping us accelerate progress in the fight against cancer.”

About Indian Cancer Genome Atlas (ICGA):
The Indian Cancer Genome Atlas (ICGA) is a national initiative focused on mapping the genomic, transcriptomic, and proteomic landscapes of cancers across India. As a section 8 not-for-profit organization, the ICGA Foundation, operates through a public-private-philanthropic partnership, with active support from over 50 clinicians, researchers, and data analysts. Its mission is to enhance cancer diagnosis and treatment for Indian patients and contribute to the global understanding of cancer biology. The foundation’s first project focuses on the multi-omics profiling of breast cancer, with plans to extend this effort to other types of cancer in the future.

https://www.icga.in/

View original content:https://www.prnewswire.com/in/news-releases/indian-cancer-genome-atlas-launches-the-countrys-first-comprehensive-cancer-multi-omics-data-portal-302254777.html